Abstract
One of the major questions remaining in thrombolysis is which drug we should be using. In terms of “head to head” comparisons there are few data. Streptokinase and tissue plasminogen activator have been compared in terms of patency and tissue plasminogen activator has been shown to be superior (1, 2). However, patency cannot be directly extrapolated to patient benefit and direct comparisons of the effects of these drugs on left ventricular function and mortality are required. Left ventricular function can be considered as a surrogate for mortality but in addition the assessment of left ventricular function also evaluates the capacity of a patient to exercise, and relates to quality of life. In this study the effects of streptokinase and tissue plasminogen activator on left ventricular function were compared.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
J. H. Chesebro, G. Knatterud, R. Roberts et al, Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous plasminogen activator and intravenous streptokinase, Circulation,76:142–54 (1987).
M. Verstraete, R. Bernard, M. Bory et al, Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction, Lancet, I:842–7 (1985).
H. D. White, R. M. Norris, M. A. Brown, P. W. T. Brandt, R. M. L. Whitlock, and C. J. Wild, Left ventricular end-systolic volume is the major determinant of survival after recovery from myocardial infarction, Circulation, 76:44–51 (1987).
R. M. Norris and H. D. White, Therapeutic trials in coronary thrombolysis should measure left ventricular function as the primary end-point of treatment, Lancet,I:1046 (1988).
H. D. White, R. M. Norris, M. A. Brown et al, Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction, N. Engl. J. Med., 317:850–5 (1987).
P. W. Serruys, M. L. Simoons, H. Suryapranata et al, Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction, J. Am. Coll. Cardiol.,7:729–42 (1986).
F. Van der Werf, and A. E. R. Arnold for the European cooperative study group for recombinant tissue type plasminogen activator (rt-PA), Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction, Br. Med. J., 297:1374–9 (1988).
M. L. Simoons, P. W. Serruys, M. van den Brand et al., Improved survival after early thrombolysis in acute myocardial infarction, Lancet, II:578–81 (1985).
M. L. Stadius, C. Maynard, J. K. Fritz et al. Coronary anatomy and left ventricular function in the first 12 hours of acute myocardial infarction: the Western Washington randomised intracoronary streptokinase trial, Circulation, 72:292–301 (1985).
E. J. Topoi, R. M. Califf, B. S. George et al, Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials, J. Am. Coll. Cardiol., 12:24A–31A (1988).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media New York
About this chapter
Cite this chapter
White, H.D. (1990). The Effects of Streptokinase and Tissue Plasminogen Activator on Left Ventricular Function. In: Liu, C.Y., Chien, S. (eds) Fibrinogen, Thrombosis, Coagulation, and Fibrinolysis. Advances in Experimental Medicine and Biology, vol 281. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3806-6_40
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3806-6_40
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6697-3
Online ISBN: 978-1-4615-3806-6
eBook Packages: Springer Book Archive